FDA approves Daraxonrasib for pancreatic cancer treatment

The FDA has granted approval for Daraxonrasib, a new therapeutic agent targeting pancreatic cancer. While the drug is being characterized as a breakthrough, its broader efficacy across other tumor types remains to be clinically validated.